Zosuquidar has significantly lower affinity for CYP3A than for P-gp [13] and phase I trials have shown that zosuquidar can be given safely to the AML patients in combination with daunorubicin and cytarabine [14,15]. This evidence concerns the gene PGP and acute myeloid leukemia.